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Pathophysiology of Colorectal Cancer
Jessica Okey BSN, RN
Otterbein University, Westerville, Ohio
Colorectal Cancer
Colorectal cancer (CRC) is a slow developing
preventable cancer that occurs after colon or
rectal polyps undergo abnormal cellular
changes. Even though CRC is preventable, it
remains the third most common cancer in the
world (Simonsom, 2018) and the second most
diagnosed cancer in developed countries
(Cuthbert, Hemmelgarn, Xu, & Cheung,
2018). There were estimates that 140,250
cases of CRC would be diagnosed in 2018 and
50,630 deaths (Montminy, Karlitz, &
Landreneau, 2019). Many CRCs can be
prevented by early detection of growths or
polyps on the colon before they develop into
cancer cells, but up to 65% of patients do not
complete recommended screenings (Hassan,
Kaminski, & Repici, 2018). To prevent
occurrences of CRC it is be important to
understand the barriers that patients have and
reason why they are not compliant with CRC
screening recommendations.
Image 1 (Buccafusca et al., 2019)
Why choose 
Colorectal Cancer?
The topic CRC was chosen because the author
is employed in a gastrointestinal endoscopy unit
and is a part of a team that completes routine
colorectal cancer screenings. The author would
like to gain a deeper understanding of the
pathophysiology of this disease.
Case Presentation
A 65 year old Caucasian male presents. to an
outpatient colonoscopy center to have his first
colonoscopy. He does not have any symptoms
and did not want to have the screening. His
wife insisted that he completed the screening.
He eventually agreed to have a colonoscopy
completed. The colonoscopy was performed
and there was a 5 cm polyp noted near the
cecum. The polyp was removed with a snare
and sent to pathology for analysis. The
pathology report came back showing
adenocarcinoma. The patient was referred to a
colorectal surgeon and oncologist for further
recommendations.
Underlying Pathophysiology
CRC can be sporadic, hereditary, or from inflammatory bowel disease
(Simonsom, 2018). There are multiple mutations that happen to cause CRC,
listed below are some of the most common causes. Sporadic causes of CRC
occur at 94%, 5% are from inherited mutations, and the remaining 1% are
from inflammatory bowel disease (Simonsom, 2018). Image 2 shows normal
colon mucosa transforming to adenocarcinoma due to DNA mutations.
Sporadic
• Chromosome instability or suppressor pathway dysfunction
§ A genetic alterations in tumor suppressor genes (APC, KRAS, and
p53)
§ When there are mutations in the tumor suppressor genes, tumors are
able to proliferate and differentiate into cancer (Simonsom, 2018)
• Microsatellite instability or mutator pathway dysfunction
§ Disruption in the DNA mismatch repair (MMR) genes
§ The MMR system proofreads DNA as it is created. When the MMR
system identifies an abnormality in the sequence repairs to the DNA are
made.
§ MMR gene dysfunction allow DNA mutations to increase at a rapid
pace (Simonsom, 2018)
• CpG island methylator phenotype (CIMP) or serrated pathway dysfunction
§ Tumor suppressor genes switch off
§ When tumor suppressor genes are turned off in the CIMP pathway
abnormal cells are able to grow and malignant cells develop (Simonsom,
2018)
Hereditary
• Lynch syndrome (LS) or hereditary nonpolyposis CRC
§ Autosomal dominant
§ Defective MMR gene (Snyder & Hampel, 2019)
§ This mutation has an increased risk for not only CRC but also ovarian,
gastric, urothelial, hepatobiliary, pancreatic, small bowel, glioblastomas,
and sebaceous skin cancers (Snyder & Hampel, 2019)
• Familial Adenomatous Polyposis (FAP)
§ Autosomal dominant
§ APC gene mutation (Snyder & Hampel, 2019)
§ Patients that have inherited FAP have hundreds of polyps in the colon
and 100% of patients with this genetic condition will get CRC by the age
of 40 (Simonsom, 2018).
§ These patient must undergo early screening and most need a colectomy
due to the number of polyps that develop in their colon and their risk of
developing cancer.
Inflammatory Bowel Disease (IBD)
• Crohn’s disease or ulcerative colitis
§ Chronic inflammation from cytokines and chemokines alter cell
proliferation and survival (Dulia, Sandborn, & Gupta, 2016)
§ The colon experiences molecular changes with inflammation,
including cytokine secretion, vascularization, and tumor growth (see
Figure 1)
§ Patients with IBD have a 60% higher risk for developing CRC
compared to those without IBD (Dulia, Sandborn, & Gupta, 2016)
Image 2  (Strubberg & Madison, 2017)
Significance of Pathophysiology
Altered genes and mutations cause cells to proliferate in the colon and polyps develop in the mucosa. The
polyps continue to grow and they eventually become malignant growths with the potential to metastasize.
Usually CRC is a slow developing cancer. Polyps can take years to turn into cancerous cells (with the
exception of FAP/LS which has rapid growth). Polyps that are less than 1 cm in size have a 3% chance of
being an advanced adenoma and polyps that are bigger than 2 cm have a 10% chance of being malignant
(Harisinghani, Chen, & Weissleder, 2019).




• Sessile serrated- these polyps may be difficult to discover as they are usually flat (Simonsom, 2018)
• Hyperplastic- these polyps have no malignant potential (Harisinghani, Chen, & Weissleder, 2019)
Treatment of CRC
Treatment of CRC depends on the stage of the tumor when it is discovered. If the tumor has not breeched
the submucosa or colon wall it may be sufficient to remove the tumor endoscopically. If the tumor is too
large to remove endoscopically surgical resection may be required. When surgical resection is required
the patient may need a bowel diversion. Below are the different treatment options for CRC.
• Primary colon cancers without systemic disease are treated mainly by surgery with complete 
mesocolic excision
• Total mesorectal excision (TME) is indicated for rectal cancer
• Right hemicolectomy transverse colectomy, left hemicolectomy or total colectomy depending on 
where the tumor is located
• Adjuvant chemotherapy
• Radiation (Buccafusca et al., 2019)





• Changes in bowel habits
• Rectal bleeding and/or melena (Buccafusca et al., 2019)
Figure 1 (Dulia, Sandborn, & Gupta, 2016)
Nursing Implications
Nurses are responsible for health promotion. When considering CRC,
nurses can promote health by encouraging patients to undergo preventative
screenings for CRC. Many CRCs can be prevented by early detection of
growths or polyps on the colon before they develop into cancer cells, but up
to 65% of patients do not complete recommended screenings (Hassan,
Kaminski, & Repici, 2018). It is important for nurses to understand the
screening methods and the recommendations that are used to detect CRC.
Nurses can help patients overcome barriers they may face when considering
CRC screenings. Below is information about the types of screenings and the
screening recommendations (see Figure 2) for patients that do not have
family history of CRC and are considered to be in a low risk group. These
screenings should start at age 50 (Rex et al., 2017). Colonoscopy is
recommended for patients that are in the high risk population. Frequency of
the screenings depend on each specific case.
CRC screening methods
• Colonoscopy is direct visualization of the entire colon (from the cecum
to the rectum) where polyps or growths can be found. If polyps are
noted they can be removed or biopsied and sent for analysis at the time
of the procedure.
• Fecal Immunochemical Testing (FIT) analyzes stool samples for
blood.
• CT colonography is an imaging test that can detect growths in the
colon.
• Flexible sigmoidoscopy is a procedure similar to colonoscopy, but the
endoscope only visualizes part of the colon, the transverse and
ascending colon are not visualized during a sigmoidoscopy.
• FIT-Fecal DNA testing (Cologuard) is a test that is able to detect
abnormal DNA that is found in some polyps and adenomas .
• When any of the screening tests come back abnormal or positive a
colonoscopy would be recommended. If patients do undergo
colonoscopy are found to have polyps the frequency of screenings
may increase to every three to five years.
Screening recommendations
Tier 1
• Colonoscopy- to be completed every 10 years
or
• Fecal Immunochemical Testing (FIT)- to be completed every year
Tier 2- If patient declines colonoscopy or FIT testing
• CT colonography- to be completed every five years
or
• Flexible sigmoidoscopy- to be completed every five to 10 years
or
• FIT- Fecal DNA testing- to be completed every three years
Tier 3- If patient declines all other screening methods
• Capsule colonoscopy- to be completed every 3 years (Rex et al., 2017)
Figure 2 (Rex et al., 2017) 
Conclusion
CRC is a preventable disease that continues to be one of the leading causes of
cancer. Multiple complex genetic mutations take place to turn normal cells
into malignant growths. If the abnormal growths are found in the very early
stages, they can be removed endoscopically, but once the mass gets too large
surgical resection is necessary. Many patients fail to complete screening for
CRC. In many cases CRC could be prevented if the screenings were
completed. Healthcare providers must ensure their patients understand the
importance of screening for CRC and promote the completion of preventative
screenings.
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